文献速递免疫规划

柯萨奇病毒B1疫苗的优化生产与纯化及其在小鼠模型中的临床前评价

Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model.
PubMed 文献 · Vaccine · 2017-06-01

研究优化了福尔马林灭活柯萨奇病毒B1(CVB1)疫苗的生产工艺,包括感染复数、培养时间、培养基、纯化方法和制剂,并在小鼠模型中评价安全性和免疫原性。两种纯化方法分别使病毒浓度提高19倍(0.06µg/cm2)和83倍(0.24µg/cm2),灭活疫苗诱导强病毒中和抗体应答并保护小鼠抵抗CVB1攻击。

要点

  • 优化了CVB1疫苗生产的感染复数、培养时间、培养基和纯化方法。
  • PEG沉淀+明胶色谱+蔗糖垫层三步法使病毒浓度提高19倍(0.06µg/cm2)。
  • 串联蔗糖沉淀法使病毒浓度提高83倍(0.24µg/cm2),但劳动强度大且难以放大。

核心结论

  • 优化后的CVB1疫苗生产工艺可产生高病毒产量,灭活疫苗在小鼠中诱导强病毒中和抗体应答并保护抵抗CVB1攻击。

研究设计与样本

  • 研究优化福尔马林灭活CVB1疫苗的生产步骤,并在小鼠模型中评价安全性和免疫原性。

主要发现

  • PEG沉淀+明胶色谱+蔗糖垫层三步纯化法使病毒浓度提高19倍(0.06µg/cm2),优于金标准方法。
  • 串联蔗糖沉淀法(无PEG沉淀步骤)使病毒浓度提高83倍(0.24µg/cm2),但劳动强度更大且无法有效放大。
  • 两种纯化方案的病毒产量均远高于传统PEG沉淀+蔗糖梯度超速离心方案。
  • 福尔马林灭活CVB1疫苗在接种小鼠中诱导强病毒中和抗体应答,保护抵抗CVB1病毒攻击。

局限性

  • 串联蔗糖沉淀法劳动强度更大且无法有效放大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coxsackie B viruses are among the most common enteroviruses, causing a wide range of diseases. Recent studies have also suggested that they may contribute to the development of type 1 diabetes. Vaccination would provide an effective way to prevent CVB infections, and the objective of this study was to develop an efficient vaccine production protocol for the generation of novel CVB vaccines. Various steps in the production of a formalin-inactivated Coxsackievirus B1 (CVB1) vaccine were optimized including the Multiplicity Of Infection (MOI) used for virus amplification, virus cultivation time, type of cell growth medium, virus purification method and formulation of the purified virus. Safety and immunogenicity of the formalin inactivated CVB1 vaccine was characterized in a mouse model. Two of the developed methods were found to be optimal for virus purification: the first employed PEG-precipitation followed by gelatin-chromatography and sucrose cushion pelleting (three-step protocol), yielding 19-fold increase in virus concentration (0.06µg/cm2) as compared to gold standard method. The second method utilized tandem sucrose pelleting without a PEG precipitation step, yielding 83-fold increase in virus concentration (0.24µg/cm2), but it was more labor-intensive and cannot be efficiently scaled up. Both protocols provide radically higher virus yields compared with traditional virus purification protocols involving PEG-precipitation and sucrose gradient ultracentrifugation. Formalin inactivation of CVB1 produced a vaccine that induced a strong, virus-neutralizing antibody response in vaccinated mice, which protected against challenge with CVB1 virus. Altogether, these results provide valuable information for the development of new enterovirus vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hankaniemi MM, Laitinen OH, Stone VM, et al. Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model. Vaccine. 2017. PMID: 28579231. doi:10.1016/j.vaccine.2017.05.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。